# Post-Market Clinical Follow-up (PMCF) Plan Template

**Regulatory Reference**: EU MDR Annex XIV Part B
**Template Version**: 1.0.0
**Last Updated**: 2025-02-09
**Valid For**: EU MDR Class IIa, IIb, III Devices

---

## Document Information

| Field | Value |
|-------|-------|
| **Device Name** | [Enter device name] |
| **Manufacturer** | [Enter manufacturer name] |
| **PMCF Plan Version** | [Enter version number] |
| **Date of Issue** | [Enter date] |
| **PMCF Period** | [Start date] to [End date] |
| **Responsible Person** | [Enter name and qualifications] |

---

## Revision History

| Version | Date | Changes | Author |
|---------|------|---------|--------|
| 1.0 | [Date] | Initial PMCF plan | [Name] |

---

## Table of Contents

1. [Executive Summary](#1-executive-summary)
2. [PMCF Rationale](#2-pmcf-rationale)
3. [PMCF Objectives](#3-pmcf-objectives)
4. [PMCF Methods](#4-pmcf-methods)
5. [Data Collection Protocol](#5-data-collection-protocol)
6. [Data Analysis Plan](#6-data-analysis-plan)
7. [Timeline and Milestones](#7-timeline-and-milestones)
8. [Resources and Responsibilities](#8-resources-and-responsibilities)
9. [Ethical Considerations](#9-ethical-considerations)
10. [Appendices](#10-appendices)

---

## 1. Executive Summary

**[Brief summary of PMCF plan, typically 1 page]**

### 1.1 Device Background

- **Device**: [Device name and model]
- **Classification**: [MDR risk class]
- **Intended Use**: [Brief description]
- **Market Status**: [CE marked date, countries marketed]

### 1.2 PMCF Necessity Assessment

**Why PMCF is required for this device**:

- [X] Device is implantable
- [X] Device is Class III
- [X] Device incorporates novel technology
- [X] Limited pre-market clinical data
- [X] Specific conditions from notified body
- [X] Long-term safety data needed
- [X] Other: [Specify]

### 1.3 PMCF Summary

- **PMCF Duration**: [e.g., 3 years, 5 years, ongoing]
- **Study Type**: [Prospective, retrospective, registry-based, literature-based]
- **Sample Size**: [Target enrollment]
- **Primary Endpoint**: [Specify]
- **Completion Date**: [Expected date]

---

## 2. PMCF Rationale

### 2.1 Regulatory Basis

This PMCF plan is required pursuant to:

- **EU MDR Article 61**: Clinical evaluation requirements
- **EU MDR Annex XIV Part B**: PMCF requirements
- **MEDDEV 2.7.1 rev 4**: Clinical evaluation guidance

### 2.2 Clinical Evaluation Gaps

**Identified gaps in pre-market clinical evaluation**:

| Gap | Impact | PMCF Approach |
|-----|--------|---------------|
| [Gap 1] | [Safety/Performance concern] | [PMCF method to address] |
| [Gap 2] | [Safety/Performance concern] | [PMCF method to address] |
| [Gap 3] | [Safety/Performance concern] | [PMCF method to address] |

### 2.3 Specific Questions to be Addressed

This PMCF will address the following clinical questions:

1. **Safety Question 1**: [Long-term safety concern]
2. **Safety Question 2**: [Rare adverse event detection]
3. **Performance Question 1**: [Durability over time]
4. **Performance Question 2**: [Real-world effectiveness]
5. **Benefit-Risk Question**: [Confirm favorable benefit-risk profile]

---

## 3. PMCF Objectives

### 3.1 Primary Objectives

1. **Confirm safety and performance** of [Device Name] in routine clinical practice
2. **Detect rare adverse events** not identified in pre-market studies
3. **Assess long-term outcomes** over [specify duration]

### 3.2 Secondary Objectives

1. Evaluate effectiveness in [specific patient subgroups]
2. Assess device performance in [specific use conditions]
3. Compare real-world outcomes to [comparator/alternative]
4. Identify [specific safety signals] requiring monitoring

### 3.3 Exploratory Objectives

1. Investigate [hypothesis 1]
2. Explore [hypothesis 2]
3. Generate hypotheses for [future research]

---

## 4. PMCF Methods

### 4.1 Study Design

| Parameter | Specification |
|-----------|---------------|
| **Study Type** | [Prospective cohort, Registry, Cross-sectional, Case series] |
| **Study Setting** | [Multi-center, Single-center, Hospital-based, Office-based] |
| **Study Duration** | [Total duration] |
| **Follow-up Period** | [Per participant] |
| **Study Sites** | [Number and geographic distribution] |

### 4.2 Study Population

#### Inclusion Criteria

1. Age ≥ [X] years
2. Diagnosis of [condition]
3. Indicated for [procedure/use]
4. Signed informed consent (if applicable)
5. [Other criteria]

#### Exclusion Criteria

1. Contraindications per IFU
2. Participation in conflicting study
3. [Other criteria]

### 4.3 Sample Size Justification

**Target Enrollment**: [N=XXX]

**Sample Size Rationale**:

- Statistical power: [X%] to detect [effect size]
- Precision: [±X%] for primary endpoint
- Rare adverse event detection: [Event rate of X] with [X%] confidence

### 4.4 Data Sources

1. **Clinical Investigation Data**:
   - [Study 1 description]
   - [Study 2 description]

2. **Post-Market Surveillance Data**:
   - Complaint reports
   - Adverse event reports
   - Field safety corrective actions

3. **Registry Data**:
   - [Registry name and description]
   - [Data access method]

4. **Published Literature**:
   - Ongoing literature surveillance
   - [Database sources]

5. **Real-World Evidence**:
   - Electronic health records
   - Claims databases
   - Patient-reported outcomes

---

## 5. Data Collection Protocol

### 5.1 Data Collection Methods

| Data Type | Collection Method | Frequency |
|-----------|-------------------|-----------|
| **Demographics** | [Case report form, EHR extraction] | Baseline |
| **Clinical Outcomes** | [Follow-up visit, remote monitoring] | [Specify schedule] |
| **Adverse Events** | [Spontaneous reports, active surveillance] | Continuous |
| **Device Performance** | [Device logs, performance testing] | [Specify schedule] |
| **Patient-Reported Outcomes** | [Questionnaire, interview] | [Specify schedule] |

### 5.2 Data Elements to be Collected

#### Baseline Data

- Patient demographics (age, sex, ethnicity)
- Relevant medical history
- Indication for device use
- Baseline clinical status
- Alternative treatments considered

#### Procedural Data (if applicable)

- Procedure details
- Device configuration/settings
- Operator experience
- Procedural complications

#### Follow-up Data

- Clinical outcome measures
- Device performance parameters
- Adverse events (serious and non-serious)
- Device-related interventions
- Patient satisfaction
- Quality of life measures

#### Adverse Event Data

- Event description
- Event severity (mild, moderate, severe)
- Event seriousness (per MDR definition)
- Causality assessment
- Outcome (resolved, ongoing, fatal)
- Interventions required

### 5.3 Data Collection Timeline

| Timepoint | Data Collection | Method |
|-----------|-----------------|--------|
| **Baseline** | Demographics, medical history | EHR/CRF |
| **Immediate** | Procedure data, immediate outcomes | EHR/CRF |
| **X days** | Early outcomes, early AEs | Follow-up/remote |
| **X months** | Primary endpoint assessment | Follow-up/remote |
| **X months** | Secondary endpoint assessment | Follow-up/remote |
| **Annually** | Long-term outcomes | Follow-up/remote |

### 5.4 Data Quality Assurance

**Data Validation Procedures**:

1. Source data verification for [X%] of records
2. Automated range and consistency checks
3. Query generation for missing or inconsistent data
4. Data monitoring committee oversight (if applicable)

**Data Completeness Targets**:

- Primary endpoint: ≥[X%] complete
- Secondary endpoints: ≥[X%] complete
- Adverse events: ≥[95%] complete

---

## 6. Data Analysis Plan

### 6.1 Statistical Analysis

#### Primary Endpoint Analysis

- **Endpoint**: [Specify]
- **Analysis Population**: [Intent-to-treat, Per-protocol, etc.]
- **Statistical Method**: [e.g., Kaplan-Meier survival analysis]
- **Success Criteria**: [Specify statistical criteria]

#### Secondary Endpoint Analysis

[Repeat structure for each secondary endpoint]

#### Safety Analysis

- **Adverse Event Rate**: [Calculation method]
- **Serious Adverse Event Rate**: [Calculation method]
- **Time-to-Event Analysis**: [Method]
- **Subgroup Analysis**: [Planned subgroups]

### 6.2 Interim Analysis

**Interim Analysis Plan**:

- **Number of Interim Analyses**: [X]
- **Interim Analysis Timepoints**: [Specify]
- **Stopping Rules**: [For safety, efficacy, futility]
- **Data Monitoring Committee**: [Yes/No, composition]

### 6.3 Data Review and Reporting

**Data Review Schedule**:

- Quarterly: Data completeness and quality
- Semi-annually: Safety data review
- Annually: Full data analysis and report

**Reporting Plan**:

1. **Annual PMCF Report** to notified body
2. **Adverse Event Reports** per regulatory timelines
3. **Trend Reports** per MDR Article 88
4. **PSUR Updates** as applicable

---

## 7. Timeline and Milestones

### 7.1 PMCF Timeline

```
┌─────────────────────────────────────────────────────────┐
│ PMCF Phase Timeline                                      │
├─────────────────────────────────────────────────────────┤
│                                                          │
│  Q1        Q2        Q3        Q4        Q1        Q2    │
│  │         │         │         │         │         │    │
│  ▼         ▼         ▼         ▼         ▼         ▼    │
│                                                          │
│  ┌──────────────────────────────────────────────────┐   │
│  │ Site Initiation    Data Collection    Analysis   │   │
│  └──────────────────────────────────────────────────┘   │
│                                                          │
└─────────────────────────────────────────────────────────┘
```

### 7.2 Key Milestones

| Milestone | Target Date | Actual Date | Status |
|-----------|-------------|-------------|--------|
| **PMCF Plan Approval** | [Date] | [Date] | [Planned/Completed] |
| **Site Initiation** | [Date] | [Date] | [Planned/Completed] |
| **First Patient Enrolled** | [Date] | [Date] | [Planned/Completed] |
| **50% Enrollment** | [Date] | [Date] | [Planned/Completed] |
| **100% Enrollment** | [Date] | [Date] | [Planned/Completed] |
| **Last Patient Last Visit** | [Date] | [Date] | [Planned/Completed] |
| **Database Lock** | [Date] | [Date] | [Planned/Completed] |
| **Final Report** | [Date] | [Date] | [Planned/Completed] |
| **CER Update** | [Date] | [Date] | [Planned/Completed] |

---

## 8. Resources and Responsibilities

### 8.1 PMCF Team

| Role | Name | Qualifications | Responsibilities |
|------|------|----------------|-------------------|
| **PMCF Sponsor** | [Name] | [Credentials] | Overall accountability |
| **Principal Investigator** | [Name] | [Credentials] | Study conduct and scientific integrity |
| **Clinical Research Coordinator** | [Name] | [Credentials] | Day-to-day study management |
| **Data Manager** | [Name] | [Credentials] | Data collection and validation |
| **Biostatistician** | [Name] | [Credentials] | Statistical analysis |
| **Safety Officer** | [Name] | [Credentials] | Adverse event monitoring |
| **Quality Assurance** | [Name] | [Credentials] | Compliance and audit readiness |

### 8.2 Study Sites

| Site ID | Location | Investigator | Target Enrollment |
|---------|----------|---------------|-------------------|
| [Site 1] | [City, Country] | [Dr. Name] | [N] |
| [Site 2] | [City, Country] | [Dr. Name] | [N] |
| [Site 3] | [City, Country] | [Dr. Name] | [N] |

### 8.3 Budget and Resources

**Estimated PMCF Costs**:

| Category | Estimated Cost | Notes |
|----------|----------------|-------|
| **Site Fees** | [Amount] | Per site or per patient |
| **Data Management** | [Amount] | EDC system, data entry |
| **Statistical Analysis** | [Amount] | Biostatistician fees |
| **Monitoring** | [Amount] | CRA visits |
| **Regulatory** | [Amount] | Report preparation, submissions |
| **Administrative** | [Amount] | Oversight, documentation |
| **Contingency** | [Amount] | [X]% of total |
| **Total** | [Amount] | |

---

## 9. Ethical Considerations

### 9.1 Ethics Committee Review

**Ethics Committee Status**: [Approved/Pending/Not required]

**Submission Details**:

- Committees: [List committees]
- Submission dates: [List dates]
- Approval numbers: [List numbers]

### 9.2 Informed Consent

**Informed Consent Required**: [Yes/No]

**Consent Process**:

- [ ] Adult patients
- [ ] Pediatric patients (with parental consent)
- [ ] Surrogate consent procedures
- [ ] Opt-out procedures (if applicable)

### 9.3 Data Protection and Privacy

**GDPR Compliance**:

- Pseudonymization of patient data
- Data processing agreements in place
- Patient data access restricted to authorized personnel
- Data retention policy: [X] years after study completion
- Secure data storage and transfer protocols

### 9.4 Risk-Benefit Assessment

**Patient Risks**:

- Minimal risk from data collection
- No additional procedures required beyond standard care
- Privacy risk mitigated by data protection measures

**Patient Benefits**:

- Contribute to scientific knowledge
- Potential improvement in device safety for future patients
- No direct therapeutic benefit

---

## 10. Appendices

### Appendix A: Data Collection Forms

[Attach all case report forms and data collection instruments]

### Appendix B: Informed Consent Form

[Attach approved informed consent form template]

### Appendix C: Site Agreements

[Attach site participation agreement templates]

### Appendix D: Regulatory Correspondence

[Attach approval letters, query responses]

### Appendix E: PMCF Protocol

[Attach detailed clinical investigation protocol if applicable]

---

## Document Control

| Information | Details |
|-------------|---------|
| **Document Owner** | [Name, Title] |
| **Approved By** | [Name, Title, Signature] |
| **Approval Date** | [Date] |
| **Review Frequency** | [Annually or per regulatory requirement] |
| **Next Review** | [Date] |

---

## PMCF Effectiveness Evaluation

**At the conclusion of this PMCF plan, the following will be evaluated**:

1. **Adequacy of PMCF Data**: Were objectives achieved?
2. **Clinical Safety Confirmed**: Is safety profile acceptable?
3. **Clinical Performance Confirmed**: Is performance acceptable?
4. **Benefit-Risk Profile**: Does it remain favorable?
5. **CER Update Required**: Does CER need updating based on PMCF findings?
6. **Additional PMCF Needed**: Is further PMCF required?

**PMCF Conclusion**: [To be completed at end of PMCF period]

---

**END OF PMCF PLAN TEMPLATE**

---

## Template Usage Notes

1. **Customization Instructions**:
   - Adapt to device-specific requirements
   - Adjust sample size based on statistical requirements
   - Modify timeline based on device lifecycle

2. **Regulatory Compliance**:
   - Ensure compliance with all applicable regulations
   - Obtain notified body approval before implementation
   - Update if regulatory requirements change

3. **Integration with CER**:
   - PMCF plan should align with CER identified gaps
   - PMCF results should update CER
   - Maintain traceability between CER gaps and PMCF activities
